- Home
- BIIB vs LYB Comparison
BIIB vs LYB Comparison
Compare BIIB & LYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- LYB
- Stock Information
- Founded
- BIIB 1978
- LYB 1955
- Country
- BIIB United States
- LYB United States
- Employees
- BIIB N/A
- LYB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- LYB Major Chemicals
- Sector
- BIIB Health Care
- LYB Industrials
- Exchange
- BIIB Nasdaq
- LYB Nasdaq
- Market Cap
- BIIB 25.1B
- LYB 28.8B
- IPO Year
- BIIB 1991
- LYB N/A
- Fundamental
- Price
- BIIB $157.78
- LYB $76.39
- Analyst Decision
- BIIB Buy
- LYB Buy
- Analyst Count
- BIIB 25
- LYB 13
- Target Price
- BIIB $258.57
- LYB $100.64
- AVG Volume (30 Days)
- BIIB 1.6M
- LYB 2.9M
- Earning Date
- BIIB 10-30-2024
- LYB 01-31-2025
- Dividend Yield
- BIIB N/A
- LYB 6.90%
- EPS Growth
- BIIB 10.05
- LYB N/A
- EPS
- BIIB 11.06
- LYB 6.57
- Revenue
- BIIB $9,607,500,000.00
- LYB $40,734,000,000.00
- Revenue This Year
- BIIB N/A
- LYB N/A
- Revenue Next Year
- BIIB N/A
- LYB N/A
- P/E Ratio
- BIIB $14.26
- LYB $11.59
- Revenue Growth
- BIIB N/A
- LYB N/A
- 52 Week Low
- BIIB $153.62
- LYB $75.99
- 52 Week High
- BIIB $268.30
- LYB $107.02
- Technical
- Relative Strength Index (RSI)
- BIIB 33.43
- LYB 22.21
- Support Level
- BIIB $158.44
- LYB $81.61
- Resistance Level
- BIIB $162.62
- LYB $85.25
- Average True Range (ATR)
- BIIB 3.19
- LYB 1.49
- MACD
- BIIB 0.90
- LYB -0.40
- Stochastic Oscillator
- BIIB 35.65
- LYB 4.31
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and is also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.